Chronic Myeloid Leukemia

Common Name(s)

Chronic Myeloid Leukemia

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Chronic Myeloid Leukemia" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Chronic Myeloid Leukemia" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Chronic Myeloid Leukemia" returned 1096 free, full-text research articles on human participants. First 3 results:

Rapid oral allopurinol desensitization in a patient with chronic myeloid leukemia.
 

Author(s): Ori Toker, Ariella Tvito, Jacob M Rowe, Jacob Ashkenazi, Chezi Ganzel, Yuval Tal, Meir Shalit

Journal: Isr. Med. Assoc. J.. 2014 Jul;16(7):461-2.

 

Last Updated: 29 Aug 2014

Go To URL
Granulocyte-macrophage colony stimulating factor (GM-CSF) enhances the clinical responses to interferon-α (IFN) in newly diagnosed chronic myeloid leukemia (CML).
 

Author(s): Joshua F Zeidner, Douglas E Gladstone, Marianna Zahurak, William H Matsui, Christopher Gocke, Richard J Jones, B Douglas Smith

Journal: Leuk. Res.. 2014 Aug;38(8):886-90.

 

The majority of chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs) remain with residual disease. In contrast to TKIs, interferon (IFN) is directly toxic to CML progenitor cells, and myeloid growth factors such as GM-CSF may enhance IFN's cytotoxicity. ...

Last Updated: 22 Jul 2014

Go To URL
Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia.
 

Author(s): Ohad Benjamini, Theresa Liu Dumlao, Hagop Kantarjian, Susan O'Brien, Guillermo Garcia-Manero, Stefan Faderl, Jeffrey Jorgensen, Rajyalakshmi Luthra, Rebecca Garris, Deborah Thomas, Partow Kebriaei, Richard Champlin, Elias Jabbour, Jan Burger, Jorge Cortes, Farhad Ravandi

Journal: Am. J. Hematol.. 2014 Mar;89(3):282-7.

 

Dasatinib is a second generation tyrosine kinase inhibitor, with activity in imatinib resistant Ph-positive ALL.We have treated 34 patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia(ALL) (n519) or lymphoid blast phase of chronic myelogenous leukemia ...

Last Updated: 21 Apr 2014

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Chronic Myeloid Leukemia" returned 127 free, full-text review articles on human participants. First 3 results:

[Chronic myeloid leukemia stem cells: cross-talk with the niche].
 

Author(s): Jean-Claude Chomel, Djamel Aggoune, Nathalie Sorel, Ali G Turhan

Journal: Med Sci (Paris). 2014 Apr;30(4):452-61.

 

The physiological hematopoietic niche located in bone marrow is a pluricellular structure whose components are now well identified. Within this microenvironment, hematopoietic stem cells are in direct contact with mesenchymal stromal cells, osteoblasts and sinusoidal endothelial cells. ...

Last Updated: 7 May 2014

Go To URL
Moving towards patient-centered decision-making in chronic myeloid leukemia: assessment of quality of life and symptom burden.
 

Author(s): Michele Baccarani, Fabio Efficace, Gianantonio Rosti

Journal: Haematologica. 2014 Feb;99(2):205-8.

 

Last Updated: 5 Feb 2014

Go To URL
Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia.
 

Author(s): Elias Jabbour, Jorge Cortes, Farhad Ravandi, Susan O'Brien, Hagop Kantarjian

Journal: Semin. Hematol.. 2013 Oct;50(4):271-83.

 

Advances in the genetic and molecular characterizations of leukemias have enhanced our capabilities to develop targeted therapies. The most dramatic example of targeted therapy in cancer to date is the use of targeted BCR-ABL protein tyrosine kinase inhibitors (TKI), which has revolutionized ...

Last Updated: 19 Nov 2013

Go To URL
 
 
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase
 

Status: Recruiting

Condition Summary: Chronic Phase Philadelphia Positive; BCR-ABL Positive; Chronic Myeloid Leukaemia

 

Last Updated: 12 May 2014

Go to URL
Pulmonary Vasculopathy Under Second-line Therapy of Chronic Myeloid Leukemia
 

Status: Recruiting

Condition Summary: Chronic Myeloid Leukemia

 

Last Updated: 18 Feb 2014

Go to URL
Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib
 

Status: Recruiting

Condition Summary: Chronic Myeloid Leukemia

 

Last Updated: 30 Jan 2014

Go to URL